Stem Memory T Cells Transposon Engineering Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a long-felt need for an effective method to produce modified stem-cell memory T cells that can persist in patients as a stable population to prevent cancer relapses, as traditional biologics and chemotherapeutics do not provide long-term solutions.
Innovation Solution
The method involves introducing a transposon composition with an antigen receptor or therapeutic protein into primary human T cells, using transposases like piggyBac or Sleeping Beauty to produce modified stem memory T cells that express specific cell-surface markers, such as CD62L and CD45RA, enabling them to persist and recognize antigens effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If traditional biologics and chemotherapeutics are used, then initial tumor treatment can be achieved, but long-term persistence and prevention of cancer relapses is not accomplished
Solution Approach 1:
The patent applies preliminary action by generating stem cell memory T cells (TSCM) ex vivo before administration to the patient. These pre-generated memory T cells are engineered to recognize and respond to cancer antigens, establishing long-term protective immunity before the actual cancer threat occurs. The cells are prepared in advance with specific antigen receptors and memory phenotypes that enable immediate and sustained response upon cancer recurrence.
Solution Approach 2:
The patent implements self-service through the self-renewing capacity of stem cell memory T cells. Unlike conventional therapies that require continuous external intervention, the engineered TSCM cells autonomously maintain their population through self-renewal and provide sustained cancer surveillance. The cells serve themselves by continuously monitoring for cancer recurrence and eliminating threats without requiring repeat administrations of external biologics or chemotherapeutics.
2Speed
If modified-T cells are designed to drive tumor destruction initially, then immediate cancer response is achieved, but long-term persistence as stable memory cell population is difficult to maintain
Solution Approach 1:
The patent applies segmentation by separating the T cell population into distinct functional subsets with specialized roles. Specifically, it generates both effector T cells for immediate tumor destruction and stem cell memory T cells for long-term persistence. This segmentation allows each subset to optimize its function without compromising the other, with effector cells providing rapid response and memory cells ensuring durable protection.
Solution Approach 2:
The patent implements local quality by赋予 different functional properties to different T cell subsets based on their specific roles. Effector T cells are optimized for high cytotoxic activity and rapid tumor destruction, while stem cell memory T cells are optimized for self-renewal, stability, and long-term persistence. Each subset exhibits localized functional specialization that matches its biological purpose, with effector cells displaying high proliferative capacity and memory cells displaying high stability and self-renewal capacity.
3Reliability
If intensive efforts are focused on developing antigen receptor molecules to prevent T cell exhaustion, then T cell viability is improved, but the complexity of cell modification and engineering increases
Solution Approach 1:
The patent uses an intermediary approach by employing transposon-based genomic editing systems as mediators to introduce and stabilize antigen receptor genes in T cells. The transposon system serves as a controlled intermediary mechanism that delivers therapeutic genes without requiring complex viral vectors or multiple sequential modification steps. This intermediary tool simplifies the engineering process while ensuring reliable integration and expression of antigen receptor molecules.
Solution Approach 2:
The patent applies parameter changes by modifying specific genetic and epigenetic parameters of T cells to achieve the desired functional profile. This includes altering gene expression patterns, chromatin structure, and epigenetic marks to generate stem cell memory T cells with enhanced self-renewal and stability. By systematically adjusting these molecular parameters, the patent achieves improved T cell viability and persistence without requiring overly complex modification protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the production of modified T cells that can persist and effectively recognize antigens, potentially leading to better tumor eradication and long-term engraftment, reducing the need for repeat treatments and preventing cancer relapses.
Implementation Method 1
a transposase or a sequence encoding the transposase... wherein the modified T cell expresses one or more cell-surface marker(s) of a stem memory T cell
Implementation Method 2
a genomic editing construct may be introduced into the modified cells of the disclosure in a transposon or other means of delivery through electroporation or nucleofection
Data Source
AI summary
The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.